AU2009235490B2 - Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season - Google Patents

Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season Download PDF

Info

Publication number
AU2009235490B2
AU2009235490B2 AU2009235490A AU2009235490A AU2009235490B2 AU 2009235490 B2 AU2009235490 B2 AU 2009235490B2 AU 2009235490 A AU2009235490 A AU 2009235490A AU 2009235490 A AU2009235490 A AU 2009235490A AU 2009235490 B2 AU2009235490 B2 AU 2009235490B2
Authority
AU
Australia
Prior art keywords
allergen
dosage form
seasonal
months
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009235490A
Other languages
English (en)
Other versions
AU2009235490A1 (en
Inventor
Eckhard-Carl Albrecht Puchert
Eike Gunther Wustenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALK Abello AS
Original Assignee
ALK Abello AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39809974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009235490(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ALK Abello AS filed Critical ALK Abello AS
Publication of AU2009235490A1 publication Critical patent/AU2009235490A1/en
Application granted granted Critical
Publication of AU2009235490B2 publication Critical patent/AU2009235490B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009235490A 2008-04-11 2009-04-08 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season Ceased AU2009235490B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4440108P 2008-04-11 2008-04-11
DKPA200800533 2008-04-11
DKPA200800533 2008-04-11
US61/044,401 2008-04-11
PCT/EP2009/054186 WO2009124954A1 (en) 2008-04-11 2009-04-08 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season

Publications (2)

Publication Number Publication Date
AU2009235490A1 AU2009235490A1 (en) 2009-10-15
AU2009235490B2 true AU2009235490B2 (en) 2013-10-24

Family

ID=39809974

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009235490A Ceased AU2009235490B2 (en) 2008-04-11 2009-04-08 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season

Country Status (12)

Country Link
US (2) US9248097B2 (enExample)
EP (1) EP2265285B1 (enExample)
JP (2) JP5618981B2 (enExample)
CN (1) CN102014954A (enExample)
AU (1) AU2009235490B2 (enExample)
BR (1) BRPI0911433A2 (enExample)
CA (1) CA2720455A1 (enExample)
DE (1) DE202008006598U1 (enExample)
EA (1) EA019202B1 (enExample)
ES (1) ES2406391T3 (enExample)
MX (1) MX2010011012A (enExample)
WO (1) WO2009124954A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003280324A1 (en) * 2002-11-26 2004-06-18 Alk-Abello A/S Pharmaceutical allergen product
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
WO2012049312A1 (en) * 2010-10-15 2012-04-19 Alk-Abelló A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
MX2013003817A (es) 2010-10-15 2013-05-01 Alk Abello As Supresion de una respuesta inmunologica de hipersensibilidad con antigeno no relacionado derivado de material de fuente de alergeno.
EP2681555B1 (en) 2011-02-25 2020-04-08 Benaroya Research Institute Detection of an allergic disorder
JP2012240975A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
JP2012240978A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
EP2804613A4 (en) 2012-01-16 2015-12-09 Elizabeth Mckenna COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATORY ILLNESSES AND DISORDERS
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
RU2690675C2 (ru) 2012-08-21 2019-06-05 Санофи Байотекнолоджи Способы лечения или предотвращения астмы посредством введения антагониста il-4r
BR112015006264A2 (pt) 2012-09-21 2017-07-04 Mckenna Elizabeth composições de oligonucleotídeos cpg ocorrendo naturalmente e suas aplicações terapêuticas
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
MX2017006286A (es) 2014-11-14 2018-01-23 Sanofi Biotechnology Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
EP4442323A3 (en) 2016-09-01 2025-01-01 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
KR20250044796A (ko) 2017-10-30 2025-04-01 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
PH12021552123A1 (en) 2019-03-21 2022-08-22 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
JP7592064B2 (ja) 2019-07-16 2024-11-29 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
EP4513185A1 (en) * 2023-08-22 2025-02-26 Luxembourg Institute of Health (LIH) Early response biomarkers for allergen immunotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
WO2005083385A2 (en) * 2004-02-26 2005-09-09 Alk-Abelló A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration
WO2008116936A1 (en) * 2007-03-28 2008-10-02 Alk-Abelló A/S Use of an adjuvanted allergy vaccine formulation for parenteral administration

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK137992D0 (da) 1992-11-13 1992-11-13 Alk Lab As Fremgangsmaade til paavisning af et immunologisk aktivt stof i en proeve under anvendelse af et maerkningsstof
JPH0959179A (ja) * 1995-08-28 1997-03-04 Japan Tobacco Inc スギ花粉症予防性を有する口腔衛生剤
ES2313776T3 (es) 1998-03-16 2009-03-01 Alk-Abello A/S Alergenos recombinantes mutantes.
FR2778244B1 (fr) 1998-04-30 2000-07-13 Univ Joseph Fourier Procede d'excitation d'une cavite optique pour la detection de gaz a l'etat de traces
DE60136653D1 (de) 2000-11-16 2009-01-02 Alk Abello As Mutante allergene
EP1504089A2 (en) 2002-05-16 2005-02-09 Alk Abell A/S Allergen mutants
US8491909B2 (en) 2004-02-06 2013-07-23 Greer Laboratories, Inc. Methods and compositions for dosing of allergens
US20060115499A1 (en) 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
CA2586283A1 (en) 2004-11-10 2006-05-18 Jens Brimnes Method of preventive treatment of allergy by mucosal administration of an allergy vaccine
DK1812059T3 (da) 2004-11-10 2010-09-13 Alk Abello As Fremgangsmåde til forebyggende behandling af allergi ved mukosaadministration af en allergivaccine
CN101098711A (zh) * 2005-01-07 2008-01-02 阿尔克-阿贝洛有限公司 通过口粘膜施用变态反应疫苗预防性治疗变态反应的方法
US20060210590A1 (en) * 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
RU2008117396A (ru) 2005-10-04 2009-11-10 Альк-Абелло А/С (Dk) Твердая вакцинная композиция
EP1814516B1 (en) 2005-11-04 2012-12-26 Alk-Abelló A/S Use of a liquid allergy vaccine formulation for oromucosal administration
DE202007004567U1 (de) 2007-03-28 2007-10-11 Alk-Abelló A/S Verwendung einer adjuvierten Allergievakzinformulierung zur parenteralen Verabreichung
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
WO2005083385A2 (en) * 2004-02-26 2005-09-09 Alk-Abelló A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration
WO2008116936A1 (en) * 2007-03-28 2008-10-02 Alk-Abelló A/S Use of an adjuvanted allergy vaccine formulation for parenteral administration

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Dahl et al (2008) Journal of Allergy and Clinical Immunology, February, 121(2):512-518 *
Kopp et al (2007) Allergo Journal, December, 16(8):570-575 *
Novembre et al (2004) Journal of Allergy and Clinical Immunology, October, 114(4):851-857 *
Ott et al (2007) Allergy, June, 62(Suppl 83):72 *
Seidenberg et al (2006) Clinical and Experimental Allergy, September, 36(9):1205-1206 *

Also Published As

Publication number Publication date
CN102014954A (zh) 2011-04-13
ES2406391T3 (es) 2013-06-06
MX2010011012A (es) 2010-11-12
WO2009124954A1 (en) 2009-10-15
JP2011516521A (ja) 2011-05-26
EP2265285A1 (en) 2010-12-29
EA201071182A1 (ru) 2011-06-30
DE202008006598U1 (de) 2008-10-02
AU2009235490A1 (en) 2009-10-15
US20140127298A1 (en) 2014-05-08
JP2015013891A (ja) 2015-01-22
US20110142934A1 (en) 2011-06-16
CA2720455A1 (en) 2009-10-15
BRPI0911433A2 (pt) 2016-07-26
EP2265285B1 (en) 2013-03-20
HK1147946A1 (en) 2011-08-26
JP5618981B2 (ja) 2014-11-05
US9248097B2 (en) 2016-02-02
EA019202B1 (ru) 2014-01-30

Similar Documents

Publication Publication Date Title
AU2009235490B2 (en) Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
JP5442924B2 (ja) アレルゲン剤形
US8012505B2 (en) Dosage form having a saccharide matrix
HK1200019A1 (en) Use of a liquid allergy vaccine formulation for oromucosal administration
MXPA05009079A (es) Forma de dosificacion que tiene una matriz de sacarido.
AU2008231722B2 (en) Use of an adjuvanted allergy vaccine formulation for parenteral administration
HK1147946B (en) Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
EP1974745B1 (en) Use of an adjuvanted allergy vaccine formulation for subcutaneous administration
CN101340892A (zh) 用于口腔粘膜给药的液体变态反应性疫苗制剂的用途
HK1110773B (en) Use of a liquid allergy vaccine formulation for oromucosal administration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired